Edwards Lifesciences Launches Philanthropic Initiative to Impact Global Burden of Heart Valve Disease

Edwards Lifesciences Launches Philanthropic Initiative to Impact Global Burden 
of Heart Valve Disease 
Goal of Supporting the Education, Screening and Treatment of One
Million Underserved People by 2020 
IRVINE, CA -- (Marketwired) -- 04/28/14 --  Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, announced today that it has
launched a significant, multi-year philanthropic initiative -- themed
Every Heartbeat Matters -- with a goal that, by 2020, its
philanthropy will impact the global burden of heart valve disease by
supporting the education, screening and treatment of one million
underserved people.  
As shared with non-profit partners in December, the company will
celebrate the 10th anniversary of The Edwards Lifesciences Fund (The
Fund) this year by launching a charitable initiative focused on
achieving one specific goal. Every Heartbeat Matters was unveiled at
an event on April 27 at the American Association for Thoracic Surgery
(AATS) Annual Meeting currently underway in Toronto. Joining Edwards
for the launch were top leaders from AATS, American College of
Cardiology, American Heart Association, Patient Advocate Foundation,
Society of Thoracic Surgeons and WomenHeart, who expressed their
engagement with Edwards' philanthropy to achieve the initiative goal
in front of attending clinicians and non-profit partners. 
"By focusing our philanthropy on a particular problem that we know
well -- the global burden of heart valve disease -- we hope to drive
a meaningful change for underserved patients," said Michael A.
Mussallem, Edwards Lifesciences' chairman and CEO. "Through Every
Heartbeat Matters, we want to inspire the most creative non-profit
minds to join us as we seek to address challenging issues to help
vulnerable patients on their path to wellness."  
"We estimate that more than 6 million people in the U.S. and millions
more around the world suffer from heart valve disease -- a disease
that is largely treatable when resources are available," said Pedro
J. del Nido, AATS president-elect, at the launch event. "Speaking for
the AATS Council, we are excited to work with Edwards' philanthropy
to develop new innovative ideas to address an issue that impacts so
many of our patients." 
The company plans to continue supporting other health- and
community-focused programs through The Fund, while committing at
least half of its charitable grants during the six-year period ending
in 2020 to Every Heartbeat Matters. In 2013, The Fund gifted $5.5
million to hundreds of non-profit organizations around the world and
the company expects to continue growing its giving consistent with
its success. More information about Every Heartbeat Matters can be
found at www.EveryHeartbeatMatters.com.  
About Edwards Lifesciences and The Edwards Lifesciences Fund
Lifesciences is the global leader in the science of heart valves and
hemodynamic monitoring. Driven by a passion to help patients, the
company partners with clinicians to develop innovative technologies
in the areas of structural heart disease and critical care
monitoring, enabling them to save and enhance lives. In 2004, the
company established The Edwards Lifesciences Fund at the Vanguard
Charitable Endowment Program to support advancements in knowledge and
improvements in quality-of-life, focusing primarily upon
cardiovascular disease and the communities where its employees live
and work. The Fund's mission is fulfilled by making grants to
qualified charitable organizations. Additional information about the
company and its Fund can be found at www.edwards.com.  
Edwards, Edwards Lifesciences the stylized E logo, and Every
Heartbeat Matters are trademarks of Edwards Lifesciences Corporation.
All other trademarks are the property of their respective owners. 
Media Contact:
Amanda C. Fowler
Investor Contact:
David K. Erickson
Press spacebar to pause and continue. Press esc to stop.